TABLE 2.

Univariate analysis for survival according to the stages

		Stage II-III				Stage IV
		HR	95.0% CI		p	HR	95.0% CI		p
Gender	Female vs. male	0.584	0.264	1.290	0.184	0.430	0.206	0.898	0.025
Age	(year)	1.027	0.993	1.062	0.117	1.000	0.974	1.026	0.986
HT	Yes vs. no	1.533	0.658	3.572	0.322	1.205	0.627	2.318	0.575
DM	Yes vs. no	1.891	0.555	6.438	0.308	1.314	0.463	3.725	0.608
CIHD	Yes vs. no	2.089	0.622	7.014	0.233	1.056	0.253	4.412	0.940
COPD	Yes vs. no	1.333	0.179	9.921	0.779	1.246	0.297	5.235	0.764
Smoking	Yes vs. no	0.551	0.237	1.280	0.166	2.501	1.174	5.326	0.018
Alcohol consumption	Yes vs. no					0.535	0.278	1.706	0.510
Dysphagia	Yes vs. no	0.260	0.086	0.782	0.016	0.459	0.186	1.133	0.091
Abdominal pain	Yes vs. no	0.731	0.274	1.950	0.531	0.791	0.376	1.664	0.536
Weight loss	Yes vs. no	0.774	0.290	2.065	0.609	0.716	0.372	1.379	0.318
ECOG PS	3–4 vs. 0–2	4.505	1.007	20.164	0.049	3.603	1.297	10.009	0.014
Grade	III vs. I-II	0.216	0.029	1.620	0.136	1.918	0.949	3.879	0.070
Surgery	Yes vs. no	0.317	0.139	0.724	0.006	1.457	0.606	3.501	0.400
Obstruction	Yes vs. no	3.627	1.543	8.525	0.003	1.294	0.666	2.511	0.447
Neoadjuvant CRT	Yes vs. no	0.281	0.118	0.668	0.004
Stage	III vs. II	4.096	1.615	10.387	0.003
Recurrence	Yes vs. no	7.301	3.027	17.609	0.001
Distant LN metastasis	Yes vs. no					1.704	1.006	2.885	0.047
Liver metastasis	Yes vs. no					3.117	1.585	6.131	0.001
Lung metastasis	Yes vs. no					0.365	0.202	0.658	0.001
Bone metastasis	Yes vs. no					0.802	0.251	2.559	0.709
Peritoneum metastasis	Yes vs. no					1.181	0.288	4.833	0.817
CT vs. BSC						0.327	0.172	0.620	<0.001

CI: Confidence interval; HR: Hazard ratio; BSC: Best supportive care; CIHD: Chronic ischemic heart disease; COPD: Chronic obstructive lung disease; CRT: Chemoradiation; CT: Chemotherapy; ECOG PS: Eastern Cooperative Oncology Group Performance Status; DM: Diabetes mellitus; HT: Hypertension; LN: Lymph node.